1. The TLR9 agonist CpG fails to enhance the acquisition of Plasmodium falciparum-specific memory B cells in semi-immune adults in Mali.
- Author
-
Traore B, Koné Y, Doumbo S, Doumtabé D, Traoré A, Crompton PD, Mircetic M, Huang CY, Kayentao K, Dicko A, Sagara I, Ellis RD, Miura K, Guindo A, Miller LH, Doumbo OK, and Pierce SK
- Subjects
- Adjuvants, Immunologic pharmacology, Adult, Antibodies, Protozoan blood, Flow Cytometry, Humans, Malaria, Falciparum immunology, Mali, Oligodeoxyribonucleotides immunology, Plasmodium falciparum immunology, Time Factors, Vaccines, Subunit immunology, B-Lymphocytes immunology, Immunologic Memory, Malaria Vaccines immunology, Malaria, Falciparum prevention & control, Oligodeoxyribonucleotides pharmacology, Toll-Like Receptor 9 antagonists & inhibitors
- Abstract
Antibodies play a key role in controlling blood stage malaria infections, and an effective blood stage malaria vaccine will likely require that it induce vaccine-specific memory B cells (MBCs). Our previous studies showed that the addition of the TLR9 agonist CpG to Plasmodium falciparum protein subunit vaccines greatly increased their efficacy in inducing MBCs in nonimmune U.S. volunteers. Here we show that in contrast the same CpG-containing malaria vaccine did not enhance the acquisition of MBCs in semi-immune adults living in Mali. Understanding the molecular basis of this apparent refractoriness to TLR9 agonist will be of significant interest in vaccine design.
- Published
- 2009
- Full Text
- View/download PDF